Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $3.09 in the prior trading day, Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.01, down -2.59%. In other words, the price has decreased by -$2.59 from its previous closing price. On the day, 4.31 million shares were traded. AKBA stock price reached its highest trading level at $3.15 during the session, while it also had its lowest trading level at $2.98.
Ratios:
Our goal is to gain a better understanding of AKBA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 7.21 whereas as Long-Term Debt/Eq ratio is at 6.10.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 798086400 and an Enterprise Value of 856675584. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.92 while its Price-to-Book (P/B) ratio in mrq is 27.09. Its current Enterprise Value per Revenue stands at 4.205 whereas that against EBITDA is 36.692.
Stock Price History:
The Beta on a monthly basis for AKBA is 1.02, which has changed by 0.9802631 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -15.71%, while the 200-Day Moving Average is calculated to be 18.16%.
Shares Statistics:
The stock has traded on average 4.69M shares per day over the past 3-months and 3953730 shares per day over the last 10 days, according to various share statistics. A total of 263.04M shares are outstanding, with a floating share count of 250.51M. Insiders hold about 5.52% of the company’s shares, while institutions hold 39.95% stake in the company. Shares short for AKBA as of 1755216000 were 24814352 with a Short Ratio of 5.29, compared to 1752537600 on 25373233. Therefore, it implies a Short% of Shares Outstanding of 24814352 and a Short% of Float of 9.46.
